IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain Article

ESI Most Cited Paper Industry Collaboration International Collaboration

cited authors

  • Nogami, Naoyuki; Barlesi, Fabrice; Socinski, Mark A.; Reck, Martin; Thomas, Christian A.; Cappuzzo, Federico; Mok, Tony S. K.; Finley, Gene; Aerts, Joachim G.; Orlandi, Francisco; Moro-Sibilot, Denis; Jotte, Robert M.; Stroyakovskiy, Daniil; Villaruz, Liza C.; Rodriguez-Abreu, Delvys; Lim, Darren Wan-Teck; Merritt, David; Coleman, Shelley; Lee, Anthony; Shankar, Geetha; Yu, Wei; Bara, Ilze; Nishio, Makoto

authors

Publication Date

  • February 1, 2022

webpage

published in

category

keywords

  • Atezolizumab
  • Bev-acizumab
  • EGFR mutation
  • IMpower150
  • Nonsquamous NSCLC

start page

  • 309

end page

  • 323

volume

  • 17

issue

  • 2